These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30830506)

  • 1. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
    Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
    AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
    Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
    Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
    Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
    Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
    Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
    J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib complexation with randomly methylated
    Erdoğar N; Akkın S; Varan G; Bilensoy E
    Pharm Dev Technol; 2021 Sep; 26(7):797-806. PubMed ID: 34219578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
    Shan F; Shao Z; Jiang S; Cheng Z
    Cancer Med; 2016 Nov; 5(11):3166-3175. PubMed ID: 27726288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
    Pang J; Xing H; Sun Y; Feng S; Wang S
    Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
    Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
    Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
    Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
    Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines.
    Otahal A; Aydemir D; Tomasich E; Minichsdorfer C
    Sci Rep; 2020 Jan; 10(1):959. PubMed ID: 31969600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation.
    Zhou X; Tao H; Shi KH
    Drug Des Devel Ther; 2018; 12():1-8. PubMed ID: 29296076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/
    Zhang H; Chen F; He Y; Yi L; Ge C; Shi X; Tang C; Wang D; Wu Y; Nian W
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28507201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
    Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME
    Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
    Gupta B; Poudel BK; Regmi S; Pathak S; Ruttala HB; Gautam M; An GJ; Jeong JH; Choi HG; Yong CS; Kim JO
    Pharm Res; 2018 Mar; 35(5):96. PubMed ID: 29536182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
    Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
    Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.
    Hussmann D; Madsen AT; Jakobsen KR; Luo Y; Sorensen BS; Nielsen AL
    Oncotarget; 2017 May; 8(20):33300-33315. PubMed ID: 28418902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
    Hong SW; Park NS; Noh MH; Shim JA; Ahn BN; Kim YS; Kim D; Lee HK; Hur DY
    Lung Cancer; 2017 Apr; 106():115-124. PubMed ID: 28285685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro.
    Biegański P; Godel M; Riganti C; Kawano DF; Kopecka J; Kowalski K
    Bioorg Chem; 2022 Feb; 119():105514. PubMed ID: 34864281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.